



(51) International Patent Classification:

A61K 39/215 (2006.01) A61K 39/39 (2006.01)
C07K 14/005 (2006.01) A61P 31/14 (2006.01)
C07K 14/165 (2006.01) C07K 16/00 (2006.01)
C07K 19/00 (2006.01)

(21) International Application Number:

PCT/US2024/018494

(22) International Filing Date:

05 March 2024 (05.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/488,565 06 March 2023 (06.03.2023) US

(71) Applicant: **AKSTON BIOSCIENCES CORPORATION** [US/US]; 100 Cummings Center, Ste 454C, Beverly, Massachusetts 01915 (US).

(72) Inventors: **ZION, Todd C.**; 16 Winter Street, Salem, Massachusetts 01970 (US). **LANCASTER, Thomas M.**; 166 Larch Row, Wenham, Massachusetts 01984 (US).

(74) Agent: **COOK, Crissa A.**; Hovey Williams LLP, 10801 Mastin Blvd., Suite 1000, Overland Park, Kansas 66210 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(54) Title: NUCLEOCAPSID ANTIGEN IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE




FIG. 1

(57) Abstract: The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 nucleocapsid protein (N-protein) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naive patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

[Continued on next page]

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

24 October 2024 (24.10.2024)